Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JASON MILLER

Allopathic & Osteopathic Physicians Psychiatry & Neurology Psychiatry

NPI
1285746974
CMS profile
194371
Location
SAN ANTONIO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$110.01

6 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $110.01 6

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Lundbeck LLC $46.46 2
Otsuka America Pharmaceutical, Inc. $30.57 2
Janssen Pharmaceuticals, Inc $17.26 1
Allergan Inc. $15.72 1

Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JASON MILLER

NPI 1285746974 · CMS profile ID 194371

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Psychiatry

SAN ANTONIO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1285746974?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JASON MILLER, NPI 1285746974, CMS profile ID 194371. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1285746974?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). JASON MILLER, NPI 1285746974, CMS profile ID 194371. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1285746974?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
JASON MILLER, NPI 1285746974, CMS profile ID 194371, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1285746974?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

6 matching records · $110.01 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 6 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–6 of 6.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Otsuka America Pharmaceutical, Inc. $11.7608/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 687439081 CMS
Otsuka America Pharmaceutical, Inc. $18.8108/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 687439079 CMS
Allergan Inc. $15.7207/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670821119 CMS
Lundbeck LLC $23.4305/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684321413 CMS
Janssen Pharmaceuticals, Inc $17.2602/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659031067 CMS
Lundbeck LLC $23.0301/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684321411 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $110.01 6
PY2020 $45.14 2
PY2021 $34.37 2
PY2023 $36.85 2
PY2025 $135.98 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2023, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2023 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2021 Principal investigator $17,303.33 9
PY2020 Principal investigator $117,506.77 50
PY2019 Principal investigator $733,525.99 145

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

145 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Allergan Inc. $261.14 12/31/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS
A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY OF RAPASTINEL AS ADJUNCTIVE THERAPY IN THE PREVENTION OF RELAPSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 670119295
Principal investigator 1 Allergan Inc. $2,043.24 12/31/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS
LVM-MD-14 PREAPMRPHASE 3DOUBLE-BLIND No dispute reported 06/30/2026 670119675
Principal investigator 1 Allergan Inc. $591.50 12/31/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS
A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670119939
Principal investigator 1 Allergan Inc. $100.00 12/31/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670122495
Principal investigator 1 Allergan Inc. $600.00 12/31/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 670123503
Principal investigator 1 Allergan Inc. $14,038.09 12/31/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670127189
Principal investigator 1 ACADIA Pharmaceuticals Inc $2,857.69 12/20/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
ACP-103-055 No dispute reported 06/30/2026 699990483
Principal investigator 1 ACADIA Pharmaceuticals Inc $5,517.30 12/20/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
ACP-103-059 No dispute reported 06/30/2026 699990525
Principal investigator 1 Allergan Inc. $520.00 12/19/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670117366
Principal investigator 1 Eisai Inc. $1,702.00 12/17/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702552551
Principal investigator 1 Eisai Inc. $1,470.00 12/17/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702552553
Principal investigator 1 Eisai Inc. $1,733.00 12/17/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702552555
Principal investigator 1 Allergan Inc. $10,627.65 12/16/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670112521
Principal investigator 1 ACADIA Pharmaceuticals Inc $40,628.33 12/05/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
ACP-103-059 No dispute reported 06/30/2026 699990443
Principal investigator 1 Allergan Inc. $3,220.50 11/13/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE No dispute reported 06/30/2026 670096423
Principal investigator 1 Allergan Inc. $6,432.45 11/13/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670096991
Principal investigator 1 Allergan Inc. $1,476.30 11/13/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE No dispute reported 06/30/2026 670097353
Principal investigator 1 Supernus Pharmaceuticals, Inc. $1,374.12 11/12/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MOLINDONE HYDROCHLORIDE EXTENDED-RELEASE TABLETS FOR THE TREATMENT OF IMPULSIVE AGGRESSION IN PEDIATRIC PATIENTS WITH ATTENTION DEFICITHYPERACTIVITY DISORDER ADHD IN CONJUNCTION WITH STANDARD ADHD TREATMENT No dispute reported 06/30/2026 705879453
Principal investigator 1 Supernus Pharmaceuticals, Inc. $3,391.32 11/12/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS
OPEN-LABEL EXTENSION STUDY TO EVALUATE THE SAFETY OF MOLINDONE HYDROCHLORIDE EXTENDED-RELEASE TABLETS FOR THE TREATMENT OF IMPULSIVE AGGRESSION IN PEDIATRIC SUBJECTS WITH ATTENTION DEFICITHYPERACTIVITY DISORDER No dispute reported 06/30/2026 705879461
Principal investigator 1 Allergan Inc. $9,081.05 11/05/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670094699
Principal investigator 1 Allergan Inc. $4,000.00 11/01/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670093495
Principal investigator 1 Allergan Inc. $666.24 10/31/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670093241
Principal investigator 1 Eisai Inc. $1,370.00 10/24/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
A Placebo-Controlled, Double-Blind, Parallel-Group, Randomized, Proof-of-Concept, Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease No dispute reported 06/30/2026 702552531
Principal investigator 1 Genentech, Inc. $5,060.00 10/24/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
PRODROMAL TO MILD AD No dispute reported 06/30/2026 681098169
Principal investigator 1 Allergan Inc. $225.00 10/22/2019 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
AN OPEN LABEL, LONG TERM SAFETY STUDY OF RAPASTINEL AS AN ADJUNCTIVE THERAPY IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER MDD. No dispute reported 06/30/2026 670088245
Principal investigator 1 Allergan Inc. $225.00 10/22/2019 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY OF RAPASTINEL AS ADJUNCTIVE THERAPY IN THE PREVENTION OF RELAPSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 670088695
Principal investigator 1 Supernus Pharmaceuticals, Inc. $7,444.67 10/22/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS
OPEN-LABEL EXTENSION STUDY TO EVALUATE THE SAFETY OF MOLINDONE HYDROCHLORIDE EXTENDED-RELEASE TABLETS FOR THE TREATMENT OF IMPULSIVE AGGRESSION IN PEDIATRIC SUBJECTS WITH ATTENTION DEFICITHYPERACTIVITY DISORDER No dispute reported 06/30/2026 705879365
Principal investigator 1 ACADIA Pharmaceuticals Inc $1,500.00 10/18/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
ACP-103-059 No dispute reported 06/30/2026 699990187
Principal investigator 1 Eisai Inc. $3,036.00 10/15/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702552533
Principal investigator 1 Eisai Inc. $1,635.00 10/15/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702552535
Principal investigator 1 Eisai Inc. $4,078.00 10/15/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702552537
Principal investigator 1 Eisai Inc. $2,904.00 10/15/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702552539
Principal investigator 1 Supernus Pharmaceuticals, Inc. $400.00 10/14/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS
ASSESSMENT OF EFFICACY AND SAFETY OF SPN-810 FOR THE TREATMENT OF IMPULSIVE AGGRESSION IA IN ADOLESCENT SUBJECTS WITH ATTENTION DEFICITHYPERACTIVITY DISORDER ADHD IN CONJUNCTION WITH STANDARD ADHD TREATMENT No dispute reported 06/30/2026 705879305
Principal investigator 1 Supernus Pharmaceuticals, Inc. $1,797.00 10/14/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS
ASSESSMENT OF EFFICACY AND SAFETY OF SPN-810 FOR THE TREATMENT OF IMPULSIVE AGGRESSION IA IN ADOLESCENT SUBJECTS WITH ATTENTION DEFICITHYPERACTIVITY DISORDER ADHD IN CONJUNCTION WITH STANDARD ADHD TREATMENT No dispute reported 06/30/2026 705879307
Principal investigator 1 Supernus Pharmaceuticals, Inc. $60.00 10/14/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS
ASSESSMENT OF EFFICACY AND SAFETY OF SPN-810 FOR THE TREATMENT OF IMPULSIVE AGGRESSION IA IN ADOLESCENT SUBJECTS WITH ATTENTION DEFICITHYPERACTIVITY DISORDER ADHD IN CONJUNCTION WITH STANDARD ADHD TREATMENT No dispute reported 06/30/2026 705879309
Principal investigator 1 Supernus Pharmaceuticals, Inc. $500.00 10/14/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS
ASSESSMENT OF EFFICACY AND SAFETY OF SPN-810 FOR THE TREATMENT OF IMPULSIVE AGGRESSION IA IN ADOLESCENT SUBJECTS WITH ATTENTION DEFICITHYPERACTIVITY DISORDER ADHD IN CONJUNCTION WITH STANDARD ADHD TREATMENT No dispute reported 06/30/2026 705879311
Principal investigator 1 Supernus Pharmaceuticals, Inc. $30.00 10/14/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS
ASSESSMENT OF EFFICACY AND SAFETY OF SPN-810 FOR THE TREATMENT OF IMPULSIVE AGGRESSION IA IN ADOLESCENT SUBJECTS WITH ATTENTION DEFICITHYPERACTIVITY DISORDER ADHD IN CONJUNCTION WITH STANDARD ADHD TREATMENT No dispute reported 06/30/2026 705879313
Principal investigator 1 Allergan Inc. $765.00 10/08/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS
LVM-MD-14 PREAPMRPHASE 3DOUBLE-BLIND No dispute reported 06/30/2026 670082863
Principal investigator 1 Allergan Inc. $1,500.00 10/08/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 670083473
Principal investigator 1 Allergan Inc. $1,500.00 10/08/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS
LVM-MD-14 PREAPMRPHASE 3DOUBLE-BLIND No dispute reported 06/30/2026 670083573
Principal investigator 1 Eisai Inc. $4,614.00 10/08/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702552527
Principal investigator 1 Eisai Inc. $1,500.00 10/08/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702552529
Principal investigator 1 ACADIA Pharmaceuticals Inc $3,877.58 10/07/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
ACP-103-059 No dispute reported 06/30/2026 699990101
Principal investigator 1 Genentech, Inc. $1,690.00 10/02/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
PRODROMAL TO MILD AD No dispute reported 06/30/2026 681095373
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $14,267.80 10/01/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
A Randomized, Double-Blind, Placebo-Controlled, Phase 4, Relapse Prevention Study Evaluating the Efficacy and Safety of Vortioxetine 5, 10 and 20 mg in Adults With Major Depressive Disorder No dispute reported 06/30/2026 686168659
Principal investigator 1 Allergan Inc. $1,300.00 09/26/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670080403
Principal investigator 1 Allergan Inc. $1,000.00 09/24/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS
LVM-MD-14 PREAPMRPHASE 3DOUBLE-BLIND No dispute reported 06/30/2026 670079773
Principal investigator 1 Allergan Inc. $12,874.40 09/20/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670078767
Principal investigator 1 Allergan Inc. $3,681.25 09/18/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE No dispute reported 06/30/2026 670076343
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $42,042.92 09/13/2019 Non-covered Recipient Entity
NEW HOPE CLINICAL RESEARCH INC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO-CONTROLLED, PARALLEL-GROUP TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CENTANAFADINE SUSTAINED-RELEASE TABLETS IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER TRIAL 405-201-00014 No dispute reported 06/30/2026 696054945
Principal investigator 1 Allergan Inc. $1,000.00 09/12/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670074965
Principal investigator 1 Supernus Pharmaceuticals, Inc. $130.00 09/10/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MOLINDONE HYDROCHLORIDE EXTENDED-RELEASE TABLETS FOR THE TREATMENT OF IMPULSIVE AGGRESSION IN PEDIATRIC PATIENTS WITH ATTENTION DEFICITHYPERACTIVITY DISORDER ADHD IN CONJUNCTION WITH STANDARD ADHD TREATMENT No dispute reported 06/30/2026 705879143
Principal investigator 1 Supernus Pharmaceuticals, Inc. $118.00 09/10/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MOLINDONE HYDROCHLORIDE EXTENDED-RELEASE TABLETS FOR THE TREATMENT OF IMPULSIVE AGGRESSION IN PEDIATRIC PATIENTS WITH ATTENTION DEFICITHYPERACTIVITY DISORDER ADHD IN CONJUNCTION WITH STANDARD ADHD TREATMENT No dispute reported 06/30/2026 705879145
Principal investigator 1 Supernus Pharmaceuticals, Inc. $150.00 09/10/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MOLINDONE HYDROCHLORIDE EXTENDED-RELEASE TABLETS FOR THE TREATMENT OF IMPULSIVE AGGRESSION IN PEDIATRIC PATIENTS WITH ATTENTION DEFICITHYPERACTIVITY DISORDER ADHD IN CONJUNCTION WITH STANDARD ADHD TREATMENT No dispute reported 06/30/2026 705879147
Principal investigator 1 Supernus Pharmaceuticals, Inc. $250.00 09/10/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS
ASSESSMENT OF EFFICACY AND SAFETY OF SPN-810 FOR THE TREATMENT OF IMPULSIVE AGGRESSION IA IN ADOLESCENT SUBJECTS WITH ATTENTION DEFICITHYPERACTIVITY DISORDER ADHD IN CONJUNCTION WITH STANDARD ADHD TREATMENT No dispute reported 06/30/2026 705879171
Principal investigator 1 Supernus Pharmaceuticals, Inc. $160.00 09/10/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
ASSESSMENT OF EFFICACY AND SAFETY OF SPN-810 FOR THE TREATMENT OF IMPULSIVE AGGRESSION IA IN ADOLESCENT SUBJECTS WITH ATTENTION DEFICITHYPERACTIVITY DISORDER ADHD IN CONJUNCTION WITH STANDARD ADHD TREATMENT No dispute reported 06/30/2026 705879173
Principal investigator 1 Supernus Pharmaceuticals, Inc. $120.00 09/10/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
ASSESSMENT OF EFFICACY AND SAFETY OF SPN-810 FOR THE TREATMENT OF IMPULSIVE AGGRESSION IA IN ADOLESCENT SUBJECTS WITH ATTENTION DEFICITHYPERACTIVITY DISORDER ADHD IN CONJUNCTION WITH STANDARD ADHD TREATMENT No dispute reported 06/30/2026 705879175
Principal investigator 1 Supernus Pharmaceuticals, Inc. $7,123.79 09/10/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS
OPEN-LABEL EXTENSION STUDY TO EVALUATE THE SAFETY OF MOLINDONE HYDROCHLORIDE EXTENDED-RELEASE TABLETS FOR THE TREATMENT OF IMPULSIVE AGGRESSION IN PEDIATRIC SUBJECTS WITH ATTENTION DEFICITHYPERACTIVITY DISORDER No dispute reported 06/30/2026 705879197
Principal investigator 1 Sunovion Pharmaceuticals Inc. $321.00 09/06/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
Dasotraline Binge Eating Disorder Extension Study No dispute reported 06/30/2026 629914813
Principal investigator 1 Sunovion Pharmaceuticals Inc. $4.11 09/06/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
Dasotraline Binge Eating Disorder Extension Study No dispute reported 06/30/2026 632155709
Principal investigator 1 ACADIA Pharmaceuticals Inc $1,500.00 09/04/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
ACP-103-059 No dispute reported 06/30/2026 699989827
Principal investigator 1 Genentech, Inc. $8,462.00 08/29/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
PRODROMAL TO MILD AD No dispute reported 06/30/2026 681075627
Principal investigator 1 Allergan Inc. $4,000.00 08/23/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670069349
Principal investigator 1 Allergan Inc. $8,053.15 08/22/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS
LVM-MD-14 PREAPMRPHASE 3DOUBLE-BLIND No dispute reported 06/30/2026 670067729
Principal investigator 1 Allergan Inc. $2,280.00 08/16/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE No dispute reported 06/30/2026 670066753
Principal investigator 1 Allergan Inc. $11,405.70 08/16/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670066981
Principal investigator 1 Sunovion Pharmaceuticals Inc. $1,750.00 08/15/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
Dasotraline Binge Eating Disorder Extension Study No dispute reported 06/30/2026 629914817
Principal investigator 1 Sunovion Pharmaceuticals Inc. $22.43 08/15/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
Dasotraline Binge Eating Disorder Extension Study No dispute reported 06/30/2026 632155719
Principal investigator 1 Eisai Inc. $1,844.00 08/13/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
A Placebo-Controlled, Double-Blind, Parallel-Group, Randomized, Proof-of-Concept, Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease No dispute reported 06/30/2026 702552541
Principal investigator 1 Sunovion Pharmaceuticals Inc. $2,030.22 08/08/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
Dasotraline Binge Eating Disorder Extension Study No dispute reported 06/30/2026 629914819
Principal investigator 1 Sunovion Pharmaceuticals Inc. $26.02 08/08/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
Dasotraline Binge Eating Disorder Extension Study No dispute reported 06/30/2026 632155723
Principal investigator 1 Supernus Pharmaceuticals, Inc. $5,999.76 08/06/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MOLINDONE HYDROCHLORIDE EXTENDED-RELEASE TABLETS FOR THE TREATMENT OF IMPULSIVE AGGRESSION IN PEDIATRIC PATIENTS WITH ATTENTION DEFICITHYPERACTIVITY DISORDER ADHD IN CONJUNCTION WITH STANDARD ADHD TREATMENT No dispute reported 06/30/2026 705878999
Principal investigator 1 Supernus Pharmaceuticals, Inc. $8,119.12 08/06/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS
OPEN-LABEL EXTENSION STUDY TO EVALUATE THE SAFETY OF MOLINDONE HYDROCHLORIDE EXTENDED-RELEASE TABLETS FOR THE TREATMENT OF IMPULSIVE AGGRESSION IN PEDIATRIC SUBJECTS WITH ATTENTION DEFICITHYPERACTIVITY DISORDER No dispute reported 06/30/2026 705879049
Principal investigator 1 Allergan Inc. $1,000.00 08/01/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE No dispute reported 06/30/2026 670063235
Principal investigator 1 Allergan Inc. $7,500.00 08/01/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE No dispute reported 06/30/2026 670063239
Principal investigator 1 Allergan Inc. $500.00 08/01/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE No dispute reported 06/30/2026 670063243
Principal investigator 1 Allergan Inc. $750.00 08/01/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE No dispute reported 06/30/2026 670063249
Principal investigator 1 Supernus Pharmaceuticals, Inc. $3,923.39 07/30/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
ASSESSMENT OF EFFICACY AND SAFETY OF SPN-810 FOR THE TREATMENT OF IMPULSIVE AGGRESSION IA IN ADOLESCENT SUBJECTS WITH ATTENTION DEFICITHYPERACTIVITY DISORDER ADHD IN CONJUNCTION WITH STANDARD ADHD TREATMENT No dispute reported 06/30/2026 705878977
Principal investigator 1 Allergan Inc. $5,406.45 07/16/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670057583
Principal investigator 1 Supernus Pharmaceuticals, Inc. $7,515.47 07/16/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS
ASSESSMENT OF EFFICACY AND SAFETY OF SPN-810 FOR THE TREATMENT OF IMPULSIVE AGGRESSION IA IN ADOLESCENT SUBJECTS WITH ATTENTION DEFICITHYPERACTIVITY DISORDER ADHD IN CONJUNCTION WITH STANDARD ADHD TREATMENT No dispute reported 06/30/2026 705878911
Principal investigator 1 Supernus Pharmaceuticals, Inc. $5,334.55 07/16/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS
OPEN-LABEL EXTENSION STUDY TO EVALUATE THE SAFETY OF MOLINDONE HYDROCHLORIDE EXTENDED-RELEASE TABLETS FOR THE TREATMENT OF IMPULSIVE AGGRESSION IN PEDIATRIC SUBJECTS WITH ATTENTION DEFICITHYPERACTIVITY DISORDER No dispute reported 06/30/2026 705878933
Principal investigator 1 Allergan Inc. $615.00 07/11/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS
LVM-MD-14 PREAPMRPHASE 3DOUBLE-BLIND No dispute reported 06/30/2026 670056303
Principal investigator 1 Allergan Inc. $400.00 07/11/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS
LVM-MD-14 PREAPMRPHASE 3DOUBLE-BLIND No dispute reported 06/30/2026 670056373
Principal investigator 1 Allergan Inc. $615.00 07/11/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS
LVM-MD-14 PREAPMRPHASE 3DOUBLE-BLIND No dispute reported 06/30/2026 670056409
Principal investigator 1 Allergan Inc. $660.00 07/09/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS
A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670055909
Principal investigator 1 Supernus Pharmaceuticals, Inc. $4,490.19 07/09/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MOLINDONE HYDROCHLORIDE EXTENDED-RELEASE TABLETS FOR THE TREATMENT OF IMPULSIVE AGGRESSION IN PEDIATRIC PATIENTS WITH ATTENTION DEFICITHYPERACTIVITY DISORDER ADHD IN CONJUNCTION WITH STANDARD ADHD TREATMENT No dispute reported 06/30/2026 705878865
Principal investigator 1 ACADIA Pharmaceuticals Inc $9,750.00 07/05/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
ACP-103-055 No dispute reported 06/30/2026 699989503
Principal investigator 1 ACADIA Pharmaceuticals Inc $1,514.00 07/05/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
ACP-103-059 No dispute reported 06/30/2026 699989517
Principal investigator 1 Allergan Inc. $712.50 07/02/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 670054737
Principal investigator 1 Allergan Inc. $14,763.00 06/25/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670052939
Principal investigator 1 Allergan Inc. $400.00 06/25/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS
LVM-MD-14 PREAPMRPHASE 3DOUBLE-BLIND No dispute reported 06/30/2026 670053585
Principal investigator 1 H. Lundbeck A S $2,983.10 06/11/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
Active Reference Fluoxetine Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years With Major Depressive Disorder MDD No dispute reported 06/30/2026 681159910
Principal investigator 1 Supernus Pharmaceuticals, Inc. $5,566.95 06/11/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MOLINDONE HYDROCHLORIDE EXTENDED-RELEASE TABLETS FOR THE TREATMENT OF IMPULSIVE AGGRESSION IN PEDIATRIC PATIENTS WITH ATTENTION DEFICITHYPERACTIVITY DISORDER ADHD IN CONJUNCTION WITH STANDARD ADHD TREATMENT No dispute reported 06/30/2026 705878721
Principal investigator 1 ACADIA Pharmaceuticals Inc $9,750.00 06/06/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
ACP-103-059 No dispute reported 06/30/2026 699989387
Principal investigator 1 Sunovion Pharmaceuticals Inc. $429.00 06/06/2019 Non-covered Recipient Entity
CLINICAL TRIAL SOURCE LLC
Dasotraline Binge Eating Disorder Extension Study No dispute reported 06/30/2026 629914815
Principal investigator 1 Sunovion Pharmaceuticals Inc. $5.49 06/06/2019 Non-covered Recipient Entity
CLINICAL TRIAL SOURCE LLC
Dasotraline Binge Eating Disorder Extension Study No dispute reported 06/30/2026 632155715
Principal investigator 1 Eisai Inc. $1,950.00 06/04/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
A Placebo-controlled, Double-blind, Parallel-group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702552543
Principal investigator 1 Eisai Inc. $1,912.30 06/04/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
A Placebo-controlled, Double-blind, Parallel-group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702552545
Principal investigator 1 Allergan Inc. $1,497.66 05/21/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS
LVM-MD-14 PREAPMRPHASE 3DOUBLE-BLIND No dispute reported 06/30/2026 670046835
Principal investigator 1 Genentech, Inc. $9,996.00 05/15/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
PRODROMAL TO MILD AD No dispute reported 06/30/2026 681081127
Principal investigator 1 Supernus Pharmaceuticals, Inc. $9,887.39 05/14/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS
OPEN-LABEL EXTENSION STUDY TO EVALUATE THE SAFETY OF MOLINDONE HYDROCHLORIDE EXTENDED-RELEASE TABLETS FOR THE TREATMENT OF IMPULSIVE AGGRESSION IN PEDIATRIC SUBJECTS WITH ATTENTION DEFICITHYPERACTIVITY DISORDER No dispute reported 06/30/2026 705878517
Principal investigator 1 Supernus Pharmaceuticals, Inc. $60.00 05/07/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MOLINDONE HYDROCHLORIDE EXTENDED-RELEASE TABLETS FOR THE TREATMENT OF IMPULSIVE AGGRESSION IN PEDIATRIC PATIENTS WITH ATTENTION DEFICITHYPERACTIVITY DISORDER ADHD IN CONJUNCTION WITH STANDARD ADHD TREATMENT No dispute reported 06/30/2026 705878459
Principal investigator 1 Supernus Pharmaceuticals, Inc. $60.00 05/07/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS
ASSESSMENT OF EFFICACY AND SAFETY OF SPN-810 FOR THE TREATMENT OF IMPULSIVE AGGRESSION IA IN ADOLESCENT SUBJECTS WITH ATTENTION DEFICITHYPERACTIVITY DISORDER ADHD IN CONJUNCTION WITH STANDARD ADHD TREATMENT No dispute reported 06/30/2026 705878485
Principal investigator 1 Supernus Pharmaceuticals, Inc. $59.00 05/07/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS
ASSESSMENT OF EFFICACY AND SAFETY OF SPN-810 FOR THE TREATMENT OF IMPULSIVE AGGRESSION IA IN ADOLESCENT SUBJECTS WITH ATTENTION DEFICITHYPERACTIVITY DISORDER ADHD IN CONJUNCTION WITH STANDARD ADHD TREATMENT No dispute reported 06/30/2026 705878487
Principal investigator 1 Allergan Inc. $2,754.05 04/23/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS
LVM-MD-14 PREAPMRPHASE 3DOUBLE-BLIND No dispute reported 06/30/2026 670039567
Principal investigator 1 Allergan Inc. $1,500.00 04/23/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 670040475
Principal investigator 1 Eisai Inc. $1,370.00 04/23/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
A Placebo-Controlled, Double-Blind, Parallel-Group, Randomized, Proof-of-Concept, Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease No dispute reported 06/30/2026 702552547
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $700.00 04/23/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
A Randomized, Double-Blind, Placebo-Controlled, Phase 4, Relapse Prevention Study Evaluating the Efficacy and Safety of Vortioxetine 5, 10 and 20 mg in Adults With Major Depressive Disorder No dispute reported 06/30/2026 686168661
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $6,082.50 04/16/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
A RANDOMIZED, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE LONGER-TERM IE, MAINTENANCE EFFICACY OF ORAL ARIPIPRAZOLE IN THE TREATMENT OF PEDIATRIC SUBJECTS WITH TOURETTE'S DISORDER No dispute reported 06/30/2026 696054170
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $117,273.84 04/15/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
AN OPEN-LABEL, 52-WEEK, MULTICENTER TRIAL EVALUATING THE LONG-TERM SAFETY AND TOLERABILITY OF CENTANAFADINE SUSTAINED-RELEASE TABLETS IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER No dispute reported 06/30/2026 696054099
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $9,422.79 04/10/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
A PHASE 1, SINGLE-DOSE, SEQUENTIAL COHORT, NONRANDOMIZED CROSSOVER TRIAL TO ASSESS THE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF ORAL BREXPIPRAZOLE IN CHILDREN 6 TO 13 YEARS OLD WITH CENTRAL NERVOUS SYSTEM DISORDERS No dispute reported 06/30/2026 696053971
Principal investigator 1 Allergan Inc. $1,500.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS
LVM-MD-14 PREAPMRPHASE 3DOUBLE-BLIND No dispute reported 06/30/2026 670035487
Principal investigator 1 Allergan Inc. $200.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS
LVM-MD-14 PREAPMRPHASE 3DOUBLE-BLIND No dispute reported 06/30/2026 670035631
Principal investigator 1 Allergan Inc. $1,499.80 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS
LVM-MD-14 PREAPMRPHASE 3DOUBLE-BLIND No dispute reported 06/30/2026 670035635
Principal investigator 1 Supernus Pharmaceuticals, Inc. $2,459.84 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS
ASSESSMENT OF EFFICACY AND SAFETY OF SPN-810 FOR THE TREATMENT OF IMPULSIVE AGGRESSION IA IN ADOLESCENT SUBJECTS WITH ATTENTION DEFICITHYPERACTIVITY DISORDER ADHD IN CONJUNCTION WITH STANDARD ADHD TREATMENT No dispute reported 06/30/2026 705878347
Principal investigator 1 Allergan Inc. $11,223.30 03/19/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS
LVM-MD-14 PREAPMRPHASE 3DOUBLE-BLIND No dispute reported 06/30/2026 670031451
Principal investigator 1 Eisai Inc. $1,950.00 03/12/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
A Placebo-controlled, Double-blind, Parallel-group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702552519
Principal investigator 1 Eisai Inc. $1,912.30 03/12/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
A Placebo-controlled, Double-blind, Parallel-group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702552521
Principal investigator 1 Eisai Inc. $24,206.08 03/12/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
A Placebo-controlled, Double-blind, Parallel-group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702552525
Principal investigator 1 Eisai Inc. $195.00 03/12/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
A Placebo-controlled, Double-blind, Parallel-group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702552549
Principal investigator 1 Supernus Pharmaceuticals, Inc. $7,173.45 03/12/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MOLINDONE HYDROCHLORIDE EXTENDED-RELEASE TABLETS FOR THE TREATMENT OF IMPULSIVE AGGRESSION IN PEDIATRIC PATIENTS WITH ATTENTION DEFICITHYPERACTIVITY DISORDER ADHD IN CONJUNCTION WITH STANDARD ADHD TREATMENT No dispute reported 06/30/2026 705877989
Principal investigator 1 Supernus Pharmaceuticals, Inc. $13,844.69 03/12/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS
ASSESSMENT OF EFFICACY AND SAFETY OF SPN-810 FOR THE TREATMENT OF IMPULSIVE AGGRESSION IA IN ADOLESCENT SUBJECTS WITH ATTENTION DEFICITHYPERACTIVITY DISORDER ADHD IN CONJUNCTION WITH STANDARD ADHD TREATMENT No dispute reported 06/30/2026 705878021
Principal investigator 1 Supernus Pharmaceuticals, Inc. $3,831.27 03/12/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS
OPEN-LABEL EXTENSION STUDY TO EVALUATE THE SAFETY OF MOLINDONE HYDROCHLORIDE EXTENDED-RELEASE TABLETS FOR THE TREATMENT OF IMPULSIVE AGGRESSION IN PEDIATRIC SUBJECTS WITH ATTENTION DEFICITHYPERACTIVITY DISORDER No dispute reported 06/30/2026 705878055
Principal investigator 1 Allergan Inc. $12,105.00 03/07/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 670029461
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $8,833.01 03/06/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, ACTIVE- AND PLACEBO-CONTROLLED TRIAL OF THE SAFETY AND EFFICACY OF OPC-64005 IN THE TREATMENT OF ADULT ATTENTION-DEFICITHYPERACTIVITY DISORDER No dispute reported 06/30/2026 696053475
Principal investigator 1 Allergan Inc. $6,484.70 02/28/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670028186
Principal investigator 1 Genentech, Inc. $3,849.00 02/25/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
PRODROMAL TO MILD AD No dispute reported 06/30/2026 681094653
Principal investigator 1 Allergan Inc. $2,314.20 02/19/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670025513
Principal investigator 1 Allergan Inc. $8,670.65 02/19/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS
LVM-MD-14 PREAPMRPHASE 3DOUBLE-BLIND No dispute reported 06/30/2026 670025715
Principal investigator 1 Genentech, Inc. $5,371.00 02/18/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
PRODROMAL TO MILD AD No dispute reported 06/30/2026 681094331
Principal investigator 1 Allergan Inc. $955.00 02/12/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670024207
Principal investigator 1 Supernus Pharmaceuticals, Inc. $2,711.37 02/12/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MOLINDONE HYDROCHLORIDE EXTENDED-RELEASE TABLETS FOR THE TREATMENT OF IMPULSIVE AGGRESSION IN PEDIATRIC PATIENTS WITH ATTENTION DEFICITHYPERACTIVITY DISORDER ADHD IN CONJUNCTION WITH STANDARD ADHD TREATMENT No dispute reported 06/30/2026 705877709
Principal investigator 1 Supernus Pharmaceuticals, Inc. $7,249.21 02/12/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS
OPEN-LABEL EXTENSION STUDY TO EVALUATE THE SAFETY OF MOLINDONE HYDROCHLORIDE EXTENDED-RELEASE TABLETS FOR THE TREATMENT OF IMPULSIVE AGGRESSION IN PEDIATRIC SUBJECTS WITH ATTENTION DEFICITHYPERACTIVITY DISORDER No dispute reported 06/30/2026 705877773
Principal investigator 1 Eli Lilly and Company $8,035.20 02/04/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
AN OPEN LABEL, LONG TERM, SAFETY STUDY OF LASMIDITAN 100 MG AND 200 MG IN THE ACUTE TREATMENT OF MIGRAINE GLADIATOR No dispute reported 06/30/2026 654289467
Principal investigator 1 Eli Lilly and Company $891.55 01/31/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
AN OPEN LABEL, LONG TERM, SAFETY STUDY OF LASMIDITAN 100 MG AND 200 MG IN THE ACUTE TREATMENT OF MIGRAINE GLADIATOR No dispute reported 06/30/2026 654288781
Principal investigator 1 Allergan Inc. $1,500.00 01/22/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS
LVM-MD-14 PREAPMRPHASE 3DOUBLE-BLIND No dispute reported 06/30/2026 670018769
Principal investigator 1 Supernus Pharmaceuticals, Inc. $9,918.36 01/22/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MOLINDONE HYDROCHLORIDE EXTENDED-RELEASE TABLETS FOR THE TREATMENT OF IMPULSIVE AGGRESSION IN PEDIATRIC PATIENTS WITH ATTENTION DEFICITHYPERACTIVITY DISORDER ADHD IN CONJUNCTION WITH STANDARD ADHD TREATMENT No dispute reported 06/30/2026 705877463
Principal investigator 1 Supernus Pharmaceuticals, Inc. $9,053.00 01/22/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS
ASSESSMENT OF EFFICACY AND SAFETY OF SPN-810 FOR THE TREATMENT OF IMPULSIVE AGGRESSION IA IN ADOLESCENT SUBJECTS WITH ATTENTION DEFICITHYPERACTIVITY DISORDER ADHD IN CONJUNCTION WITH STANDARD ADHD TREATMENT No dispute reported 06/30/2026 705877499
Principal investigator 1 Supernus Pharmaceuticals, Inc. $3,083.90 01/22/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS
OPEN-LABEL EXTENSION STUDY TO EVALUATE THE SAFETY OF MOLINDONE HYDROCHLORIDE EXTENDED-RELEASE TABLETS FOR THE TREATMENT OF IMPULSIVE AGGRESSION IN PEDIATRIC SUBJECTS WITH ATTENTION DEFICITHYPERACTIVITY DISORDER No dispute reported 06/30/2026 705877521
Principal investigator 1 Allergan Inc. $19,994.65 01/15/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS
LVM-MD-14 PREAPMRPHASE 3DOUBLE-BLIND No dispute reported 06/30/2026 670016487
Principal investigator 1 Allergan Inc. $1,500.00 01/08/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 670015697
Principal investigator 1 Supernus Pharmaceuticals, Inc. $877.50 01/08/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS
ASSESSMENT OF EFFICACY AND SAFETY OF SPN-810 FOR THE TREATMENT OF IMPULSIVE AGGRESSION IA IN ADOLESCENT SUBJECTS WITH ATTENTION DEFICITHYPERACTIVITY DISORDER ADHD IN CONJUNCTION WITH STANDARD ADHD TREATMENT No dispute reported 06/30/2026 705877407
Principal investigator 1 Supernus Pharmaceuticals, Inc. $985.50 01/08/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS
ASSESSMENT OF EFFICACY AND SAFETY OF SPN-810 FOR THE TREATMENT OF IMPULSIVE AGGRESSION IA IN ADOLESCENT SUBJECTS WITH ATTENTION DEFICITHYPERACTIVITY DISORDER ADHD IN CONJUNCTION WITH STANDARD ADHD TREATMENT No dispute reported 06/30/2026 705877409
Principal investigator 1 Supernus Pharmaceuticals, Inc. $60.00 01/08/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS
ASSESSMENT OF EFFICACY AND SAFETY OF SPN-810 FOR THE TREATMENT OF IMPULSIVE AGGRESSION IA IN ADOLESCENT SUBJECTS WITH ATTENTION DEFICITHYPERACTIVITY DISORDER ADHD IN CONJUNCTION WITH STANDARD ADHD TREATMENT No dispute reported 06/30/2026 705877411
Principal investigator 1 Eisai Inc. $1,899.00 01/03/2019 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
A Placebo-Controlled, Double-Blind, Parallel-Group, Randomized, Proof-of-Concept, Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease No dispute reported 06/30/2026 702552523